CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
驱动 CAR 时请相信你的肠道直觉
英文原题：Trust your gut when it comes to driving CARs.
查看英文原题
Trust your gut when it comes to driving CARs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞已经彻底改变了血液系统恶性肿瘤的治疗，但在可预测性差以及治疗反应中可观察到的毒性方面仍存在局限。在此，Smith等人提出，肠道微生物组是（CD19）CAR-T 细胞治疗反应和毒性的可干预（且可能可靶向）生物标志物。1。
展开英文摘要原文
Chimeric Antigen Receptor (CAR) T-cells have revolutionized the treatment of hematologic malignancies, but limitations exist in poor predictability and in observable toxicity with response to treatment. Here, Smith et al. present the gut microbiome as an actionable (and potentially targetable) biomarker of response and toxicity with (CD19) CAR T-cell treatment. 1 .
论文信息
- 作者
- Chelvanambi M、Wargo JA
- 第一作者单位
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.United States
- 通讯作者单位
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jwargo@mdanderson.org.United States
- 文献类型
- 评论
- 期刊
- Med (New York, N.Y.)2022 May 13
- 原文标识
- PubMed 35584646 · DOI 10.1016/j.medj.2022.04.015